188 related articles for article (PubMed ID: 12197549)
1. The diagnostic challenge of peritoneal mesothelioma.
Krasuski P; Poniecka A; Gal E
Arch Gynecol Obstet; 2002 Jul; 266(3):130-2. PubMed ID: 12197549
[TBL] [Abstract][Full Text] [Related]
2. [Well-differentiated papillary mesothelioma of the peritoneum: an attenuated malignant tumor. Review of the literature apropos of a case].
Bouvier S; Baron O; Nomballais F; Guillard Y; Drianno JC; Maugard-Louboutin C; Le Mevel B; De Lajartre AY; Michaud JL
Bull Cancer; 1994 Feb; 81(2):104-7. PubMed ID: 7894114
[TBL] [Abstract][Full Text] [Related]
3. Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
Koutselini HA; Lazaris AC; Thomopoulou G; Papayannopoulou A; Kairi-Vasilatou E
Adv Clin Path; 2001 Jul; 5(3):99-104. PubMed ID: 11753882
[TBL] [Abstract][Full Text] [Related]
4. Cytopathology of serous neoplasia of the ovary and the peritoneum: differential diagnosis from mesothelial proliferations.
Pisharodi LR; Bedrossian CW
Diagn Cytopathol; 1996 Nov; 15(4):292-5. PubMed ID: 8982583
[TBL] [Abstract][Full Text] [Related]
5. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
[TBL] [Abstract][Full Text] [Related]
6. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
7. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1203-14. PubMed ID: 9777982
[TBL] [Abstract][Full Text] [Related]
8. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin?
Gao FF; Krasinskas AM; Chivukula M
Appl Immunohistochem Mol Morphol; 2012 May; 20(3):272-6. PubMed ID: 22498671
[TBL] [Abstract][Full Text] [Related]
9. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
10. The role of immunohistochemistry in differentiating between peritoneal mesothelioma and ovarian serous carcinoma.
Al-Rawi HJ; Ben-Ghashir NS
Saudi Med J; 2009 Apr; 30(4):571-4. PubMed ID: 19370292
[No Abstract] [Full Text] [Related]
11. The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma.
Davidson B; Risberg B; Berner A; Bedrossian CW; Reich R
Semin Diagn Pathol; 2006 Feb; 23(1):35-43. PubMed ID: 17044194
[TBL] [Abstract][Full Text] [Related]
12. [Diffuse malignant peritoneal mesothelioma: apropos of a new case, review of the literature].
Gilly F; Pinet-Isaac S; Charret MC; Roche M; Provensal C; Braillon G
J Chir (Paris); 1989; 126(6-7):388-91. PubMed ID: 2674174
[TBL] [Abstract][Full Text] [Related]
13. Well-Differentiated Papillary Mesothelioma with Omental Calcifications: A Case Report and Review of the Literature.
Erem AS; Allamaneni SS; Braverman TS
Am J Case Rep; 2020 Jan; 21():e920487. PubMed ID: 31929500
[TBL] [Abstract][Full Text] [Related]
14. Malignant primary peritoneal mesothelioma: report of two cases and review of literature.
Dunder I; Baykal C; Turkmen I; Başsüllü N; Doğusoy GB; Demir G
Eur J Gynaecol Oncol; 2012; 33(5):549-51. PubMed ID: 23185811
[TBL] [Abstract][Full Text] [Related]
15. Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series and review of the clinical and immunohistochemical features.
Taşkın S; Gümüş Y; Kiremitçi S; Kahraman K; Sertçelik A; Ortaç F
Int J Clin Exp Pathol; 2012; 5(5):472-8. PubMed ID: 22808303
[TBL] [Abstract][Full Text] [Related]
16. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
17. Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry.
Alberti N; Serrano-Egea A; García-García E; Ballestín C; Pérez-Barrios A; López-Ríos F; de Agustín P
Acta Cytol; 2007; 51(2):203-6. PubMed ID: 17425204
[TBL] [Abstract][Full Text] [Related]
18. The differential diagnosis of primary peritoneal papillary tumors.
Gitsch G; Tabery U; Feigl W; Breitenecker G
Arch Gynecol Obstet; 1992; 251(3):139-44. PubMed ID: 1376598
[TBL] [Abstract][Full Text] [Related]
19. Benign papillary mesothelioma of the peritoneum: a consideration in the differential diagnosis of peritoneal implants.
Tzanakakis G; McCully KS; Vezeridis MP
South Med J; 1989 Dec; 82(12):1579-80. PubMed ID: 2595430
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum.
Lee YK; Jun HJ; Nahm JH; Lim TS; Park JS; Ahn JB; Rha SY; Chung HC; Oh HE; Song JS; Yang WI; Kim HS
Jpn J Clin Oncol; 2013 Oct; 43(10):996-1003. PubMed ID: 23964112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
